loading page

Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: a case report.
  • +2
  • Catherine Percy,
  • Schubert Thomas,
  • Christine Galant,
  • Thomas Kirchgesner,
  • Filomena Mazzeo
Catherine Percy
Cliniques universitaires Saint-Luc
Author Profile
Schubert Thomas
Cliniques universitaires Saint-Luc
Author Profile
Christine Galant
Cliniques universitaires Saint-Luc
Author Profile
Thomas Kirchgesner
Cliniques universitaires Saint-Luc
Author Profile
Filomena Mazzeo
Cliniques universitaires Saint-Luc
Author Profile

Abstract

NTRK gene-fusions are rare but can occur in diverse cancers. The NTRK inhibitor larotrectinib is newly approved by the FDA. This paper reports the first case of a man with a NTRK-rearranged soft tissue sarcoma treated with larotrectinib in the neoadjuvant setting, in Belgium, to avoid limb amputation.

Peer review status:Published

08 Oct 2020Submitted to Clinical Case Reports
13 Oct 2020Submission Checks Completed
13 Oct 2020Assigned to Editor
30 Oct 2020Reviewer(s) Assigned
15 Nov 2020Review(s) Completed, Editorial Evaluation Pending
16 Nov 2020Editorial Decision: Revise Minor
20 Nov 20201st Revision Received
21 Nov 2020Submission Checks Completed
21 Nov 2020Assigned to Editor
21 Nov 2020Review(s) Completed, Editorial Evaluation Pending
24 Nov 2020Editorial Decision: Accept
09 Feb 2021Published in Clinical Case Reports. 10.1002/ccr3.3878